A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs Leronlimab (Primary)
  • Indications HIV infections
  • Focus Registrational; Therapeutic Use
  • Sponsors CytoDyn
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 16 Jul 2018 Results published in the CytoDyn Media Release
    • 11 Jun 2018 Results presented at the ASM Microbe 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top